Ownership and insider activity for Artelo Biosciences, Inc. (ARTL): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory...
Price
| Price | $3.75 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-17 | MATSUI CONNIE | A-Award | 136 | $156 |
| 2026-07-17 | Blayney Douglas | A-Award | 136 | $156 |
| 2026-07-17 | Reyes Gregory | A-Award | 136 | $156 |
| 2026-07-17 | EMANUELE ROBERT MARTIN | A-Award | 136 | $156 |
| 2026-07-17 | Kelly Steven | A-Award | 136 | $156 |
| 2026-07-17 | FAVORITO TAMARA A | A-Award | 136 | $156 |
| 2026-01-30 | MATSUI CONNIE | A-Award | 292 | $499 |
| 2026-01-30 | Blayney Douglas | A-Award | 292 | $499 |
| 2026-01-30 | EMANUELE ROBERT MARTIN | A-Award | 292 | $499 |
| 2026-01-30 | Kelly Steven | A-Award | 292 | $499 |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $3590 | $572775 | $337424 | $4.4M | $2.1M | $6.6M | $6.9M | $2.8M | $2.3M | $600000 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | $3.4M | $10.6M | $7.6M | 0 | 0 |
| Receivables | 0 | 0 | $22127 | $8787 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | -$8787 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $3590 | $574275 | $396435 | $4.4M | $2.3M | $10.3M | $18.3M | $11.0M | $2.6M | $695000 |
| Property, Plant & Equipment | 0 | 0 | $563 | $721 | 0 | $90000 | $60000 | $21000 | $99000 | $64000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M | $2.0M |
| Total Assets | $3590 | $574275 | $396998 | $6.5M | $4.4M | $12.6M | $20.4M | $13.0M | $4.7M | $2.8M |
| Accounts Payable | $12940 | $28576 | $529272 | $348863 | $489000 | $471000 | $905000 | $1.2M | $1.7M | $3.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $609000 |
| Total Current Liabilities | $17390 | $29438 | $531972 | $1.0M | $501000 | $526000 | $998000 | $1.3M | $1.8M | $4.0M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $17390 | $29438 | $531972 | $1.0M | $501000 | $593000 | $1.0M | $1.3M | $1.8M | $4.1M |
| Retained Earnings | -$60200 | -$295089 | -$2.6M | -$4.8M | -$9.5M | -$16.9M | -$31.0M | -$40.3M | -$50.1M | -$63.0M |
| Total Equity | -$13800 | $544837 | -$134974 | $5.5M | $3.9M | $12.0M | $19.4M | $11.8M | $2.9M | -$1.3M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | $95000 | $63000 | $23000 | $104000 | $678000 |
| Net Debt | -$3590 | -$572775 | -$337424 | -$4.4M | -$2.1M | -$10.0M | -$17.5M | -$10.4M | -$2.2M | $78000 |
| Working Capital | -$13800 | $544837 | -$135537 | $3.4M | $1.8M | $9.8M | $17.3M | $9.7M | $785000 | -$3.3M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 3.00 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -45.94 |
Profitability
| Return on Equity | -519.09% |
| Return on Invested Capital | -219.36% |
| Return on Assets | -196.18% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CARM · GTBP · LIPO · PBM · PTIX · REVB · SLRX
Explore sector: Healthcare · Biotechnology
More sections of ARTL: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks